{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:13:23Z","timestamp":1780697603046,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016882","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:04:37Z","timestamp":1652688277000},"page":"3676-3683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identifying immunity gaps for measles using Belgian serial serology data"],"prefix":"10.1016","volume":"40","author":[{"given":"Julie","family":"Schenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Litzroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Grammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Theeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.009_b0005","unstructured":"WHO. Measles vaccines: WHO position paper \u2013 April 2017. 2017 [22\/10\/2021]. Available from: http:\/\/www.who.int\/wer."},{"issue":"47","key":"10.1016\/j.vaccine.2022.05.009_b0010","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.15585\/mmwr.mm6747a6","article-title":"Progress toward regional measles elimination \u2014 worldwide, 2000\u20132017","volume":"67","author":"Dabbagh","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"10.1016\/j.vaccine.2022.05.009_b0015","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.15585\/mmwr.mm7045a1","article-title":"Progress toward regional measles elimination \u2014 worldwide, 2000\u20132020","volume":"70","author":"Dixon","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"10.1016\/j.vaccine.2022.05.009_b0020","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.15585\/mmwr.mm6945a6","article-title":"Progress toward regional measles elimination \u2014 worldwide, 2000\u20132019","volume":"69","author":"Patel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.05.009_b0025","unstructured":"WHO. Measles resported cases and incidence 2021 [07\/04\/2022]. Available from: https:\/\/immunizationdata.who.int\/pages\/incidence\/measles.html."},{"key":"10.1016\/j.vaccine.2022.05.009_b0030","unstructured":"WHO. 9th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC) (2021). 2021."},{"key":"10.1016\/j.vaccine.2022.05.009_b0035","unstructured":"WHO. Strengthening response to measles outbreak in Ukraine. 2020."},{"key":"10.1016\/j.vaccine.2022.05.009_b0040","unstructured":"CDC. Measles Cases and Outbreaks. 2021 [22\/10\/2021]. Available from: https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html."},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.009_b0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(20)30053-0","article-title":"Measles epidemic in Samoa and other Pacific islands","volume":"20","author":"Craig","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.009_b0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1473-3099(19)30395-0","article-title":"Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis","volume":"19","author":"Nic Lochlainn","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.009_b0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1473-3099(20)30442-4","article-title":"Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis","volume":"21","author":"Schenk","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.009_b0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1473-3099(20)30522-3","article-title":"Persistence of US measles risk due to vaccine hesitancy and outbreaks abroad","volume":"20","author":"Gardner","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76746-3","article-title":"Clustering of susceptible individuals within households can drive measles outbreaks: an individual-based model exploration","volume":"10","author":"Kuylen","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1413-7","article-title":"Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination","volume":"17","author":"Funk","year":"2019","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.009_b0075","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.vaccine.2019.10.090","article-title":"The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review","volume":"38","author":"Hughes","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.009_b0080","unstructured":"WHO. Worldwide measles deaths climb 50% from 2016 to 2019 claiming over 207 500 lives in 2019. 2020 [18\/03\/2021]. Available from: https:\/\/www.who.int\/news\/item\/12-11-2020-worldwide-measles-deaths-climb-50-from-2016-to-2019-claiming-over-207-500-lives-in-2019."},{"key":"10.1016\/j.vaccine.2022.05.009_b0085","unstructured":"WHO. Implementing the Immunization Agenda 2030 2021. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/strategies\/ia2030."},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.009_b0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.vaccine.2013.10.084","article-title":"Timeliness of infant vaccination and factors related with delay in Flanders","volume":"32","author":"Lernout","year":"2014","journal-title":"Belgium Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.009_b0095","unstructured":"De Schutter I. Vaccinatie tegen mazelen, bof en rubella bij volwassenen 2018. Available from: https:\/\/www.zorg-en-gezondheid.be\/sites\/default\/files\/atoms\/files\/brief%20mazelenvaccinatie%20september%202018%20%28002%29.pdf."},{"key":"10.1016\/j.vaccine.2022.05.009_b0100","unstructured":"La rougeole : l\u2019unique protection est la vaccination. 2020 [15\/02\/2022]. Available from: https:\/\/www.vaccination-info.be\/la-rougeole-lunique-protection-est-la-vaccination\/."},{"key":"10.1016\/j.vaccine.2022.05.009_b0105","unstructured":"Adultes. 2021 [15\/02\/2022]. Available from: https:\/\/www.vaccination-info.be\/adultes\/."},{"key":"10.1016\/j.vaccine.2022.05.009_b0110","unstructured":"Permentier B. Le programme de vaccination de la federation Wallonie-Bruxelles pour les SPSE et le CPMS-WBE. 2021 [15\/02\/2022]. Available from: https:\/\/www.e-vax.be\/VaccHelp\/help\/pdf\/memo_rentree_vaccination_spse_cpms.pdf."},{"key":"10.1016\/j.vaccine.2022.05.009_b0115","unstructured":"ECDC. Disease Data from ECDC Surveillance Atlas for Measles. 2022 [27\/01\/2022]. Available from: https:\/\/www.ecdc.europa.eu\/en\/measles\/surveillance-and-disease-data\/atlas."},{"key":"10.1016\/j.vaccine.2022.05.009_b0120","unstructured":"Grammens T, Cornelissen L, Hutse V, Abady M, Theeten H, Wyndham-Thomas C, et al. Epidemiologische surveillance van mazelen Morbillivirus-2019. 2019."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0125","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.1.20998","article-title":"Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013","volume":"20","author":"Hens","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2022.05.009_b0130","doi-asserted-by":"crossref","unstructured":"Wood JG, Goeyvaerts N, MacIntyre CR, Menzies RI, McIntyre PB, Hens N. Estimating vaccine coverage from serial trivariate serologic data in the presence of waning immunity. Epidemiology (Cambridge, Mass). 2015;26(3):381-9. Epub 2015\/03\/13. doi: 10.1097\/ede.0000000000000278. PubMed PMID: 25764249","DOI":"10.1097\/EDE.0000000000000278"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.009_b0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2471\/BLT.07.041129","article-title":"Towards elimination: measles susceptibility in Australia and 17 European countries","volume":"86","author":"Andrews","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.009_b0140","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1017\/S0950268810001536","article-title":"Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium","volume":"139","author":"Theeten","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-6347-z","article-title":"Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up","volume":"19","author":"Litzroth","year":"2019","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.009_b0150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1017\/S0950268807008266","article-title":"Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia","volume":"135","author":"Tischer","year":"2007","journal-title":"Epidemiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.009_b0155","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.009_b0160","first-page":"352","article-title":"Measles vaccine","author":"Strebel","year":"2013","journal-title":"Vaccines Sixth Edition ed: Elsevier"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0165","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: A Probabilistic Programming Language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.vaccine.2022.05.009_b0170","unstructured":"Team R. R: A Language and Environment for Statistical Computing. 2021. Available from: https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.vaccine.2022.05.009_b0175","doi-asserted-by":"crossref","unstructured":"Sabbe M, Hue D, Hutse V, Goubau P. Measles resurgence in Belgium from January to mid-April 2011: a preliminary report. 2011 2011\/4\/\/. Report No.","DOI":"10.2807\/ese.16.16.19848-en"},{"key":"10.1016\/j.vaccine.2022.05.009_b0180","unstructured":"WHO. Measles. 2019 [19\/01\/2022]. Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/measles."},{"key":"10.1016\/j.vaccine.2022.05.009_b0185","doi-asserted-by":"crossref","unstructured":"Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. J Infect Dis 2018;218(3):355-64. Epub 2018\/03\/22. doi: 10.1093\/infdis\/jiy137. PubMed PMID: 29562334; PubMed Central PMCID: PMCPMC6049004.","DOI":"10.1093\/infdis\/jiy137"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.009_b0190","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2020.1871296","article-title":"Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study","volume":"17","author":"Bianchi","year":"2021","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.009_b0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2807\/ese.13.01.08002-en","article-title":"Ongoing measles outbreak in southern Bavaria, Germany","volume":"13","author":"Bernard","year":"2008","journal-title":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = Eur Commun Dis Bull"},{"key":"10.1016\/j.vaccine.2022.05.009_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ypmed.2019.02.011","article-title":"Measles outbreaks in Italy: A paradigm of the re-emergence of vaccine-preventable diseases in developed countries","volume":"121","author":"Siani","year":"2019","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2022.05.009_b0205","doi-asserted-by":"crossref","unstructured":"Smithson R, Irvine N, Hutton C, Doherty L, Watt A. Spotlight on measles 2010: ongoing measles outbreak in Northern Ireland following an imported case, September-October 2010. Euro surveillance : bulletin Europeen sur les maladies transmissibles = Eur Commun Dis Bull 2010;15(43). doi: 10.2807\/ese.15.43.19698-en.","DOI":"10.2807\/ese.15.43.19698-en"},{"issue":"20","key":"10.1016\/j.vaccine.2022.05.009_b0210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.15585\/mmwr.mm6920e1","article-title":"Decline in child vaccination coverage during the COVID-19 pandemic - Michigan care improvement registry, May 2016-May 2020","volume":"69","author":"Bramer","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.05.009_b0215","unstructured":"Cornelissen L, Hutse V, Theeten H, Wyndham-Thomas C. Epidemiologische surveillance van mazelen Morbillivirus- 2018. 2018."},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.009_b0220","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1093\/pubmed\/fdaa153","article-title":"Immunity to measles in Italian children and adolescents: a persistent problem in view of measles elimination","volume":"43","author":"Marchi","year":"2021","journal-title":"J Public Health"},{"issue":"40","key":"10.1016\/j.vaccine.2022.05.009_b0225","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.vaccine.2021.08.001","article-title":"Measles immunity over two decades in two large Italian Regions: How far is the elimination goal?","volume":"39","author":"Marchi","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.009_b0230","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/jiz380","article-title":"What is the evidence to support a correlate of protection for measles? A systematic review","volume":"221","author":"Bolotin","year":"2020","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.009_b0235","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.009_b0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/1471082X12457495","article-title":"Estimating the population prevalence and force of infection directly from antibody titres","volume":"12","author":"Bollaerts","year":"2012","journal-title":"Statistical Modelling"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:28Z","timestamp":1759403608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":48,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005795"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying immunity gaps for measles using Belgian serial serology data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}